Try our free AI Powered Acne Skin Analysis.
EFFACLAR DUO+ SPF30 protects against UV rays and environmental aggressors that can aggravate skin imperfections, fighting breakouts and minimizing the appearance of marks and blemishes. All the benefits of SPF30 protection with the comfort of a daily moisturizer.
HOW TO APPLY:
Apply to the whole face in the morning after cleansing your face with EFFACLAR FOAMING GEL. Avoid eyes contour.
Non-greasy.
With La Roche-Posay Thermal Spring Water.
Unclogs pores and improves skin texture.
Controls shine.
ANTI-UV ANTIOXIDANT XL PROTECT Technology protects skin with long UVA/UVB filters and carnosine. Tested in polluted environments.
- Well tolerated
- Hypoallergenic
- Non-comedogenic
- Tested under dermatological control
12 Months
-
Tube
-
Adults
-
Anti-imperfection
Anti-marks
Anti-UV -
Face
KEY INGREDIENTS
LET'S TAKE A LOOK INSIDE
XL-PROTECT TM SPF 30 PF 10
NIACINAMIDE
PROCERAD
B225857/1
IT'S PROVEN
VISIBLE RESULTS CONFIRMED BY CONSUMERS*
98% - Skin feels hydrated
96% - Skin is comfortable
During the day
73% - Noticeable mattifying effect
*Clinical study on 54 volunteers, self-assessments
80% - Skin looks cleaner
74% - Spots, blemishes have dried up
81% - Skin feels purified
After 4 weeks:
87% - Skin looks cleaner
80% - Skin texture is improved
EXPERT
QUOTEResist the desire to pop blemishes. It seems like a quick fix, but in reality you are likely to make the situation worse as it might increase, spread the problem or even cause scars.
WHICH ONE DO YOU NEED?
THE PERFECT MATCH
FOR YOUR SKIN
THE EFFACLAR WINNING TRIO
SEVERE IMPERFECTIONS AND MARKS
DISCOVER THE OTHER
PRODUCTS OF THE RANGE
EFFACLAR is a complete range of anti-imperfection solutions that targets all the stages of the imperfection life cycle with a high efficacy, while ensuring a perfect tolerance.
Did you
know?
The 3-step EFFACLAR routine – cleanse, correct, protect – shows proven effectiveness on patients with acne-prone skin living in polluted environments.*
*Quantitative study, Beijing/Shanghai, 2014, Total sample: n=600 ²DIM Sell-in YTD Sept 2015 ³INS/Kantar Health La Roche-Posay Barometers 2013